• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表达全长抗体的溶瘤病毒增强胶质母细胞瘤的抗肿瘤先天免疫反应。

An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma.

机构信息

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA, USA.

Department of Immuno-Oncology, Beckman Research Institute, City of Hope Comprehensive Cancer Centre, Los Angeles, CA, USA.

出版信息

Nat Commun. 2021 Oct 8;12(1):5908. doi: 10.1038/s41467-021-26003-6.

DOI:10.1038/s41467-021-26003-6
PMID:34625564
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8501058/
Abstract

Oncolytic herpes simplex virus-1 is capable of lysing tumor cells while alerting the immune system. CD47, in collaboration with SIRPα, represents an important immune checkpoint to inhibit phagocytosis by innate immune cells. Here we show locoregional control of glioblastoma by an oncolytic herpes virus expressing a full-length anti(α)-human CD47 IgG1 or IgG4 antibody. The antibodies secreted by the virus-infected glioblastoma cells block the CD47 'don't eat me' signal irrespective of the subclass; however, αCD47-IgG1 has a stronger tumor killing effect than αCD47-IgG4 due to additional antibody-dependent cellular phagocytosis by macrophages and antibody-dependent cellular cytotoxicity by NK cells. Intracranially injected αCD47-IgG1-producing virus continuously releases the respective antibody in the tumor microenvironment but not into systemic circulation; additionally, αCD47-IgG1-producing virus also improves the survival of tumor-bearing mice better than control oncolytic herpes virus combined with topical αCD47-IgG1. Results from immunocompetent mouse tumor models further confirm that macrophages, and to a lesser extent NK cells, mediate the anti-tumor cytotoxicity of antibody-producing oncolytic herpesviruses. Collectively, oncolytic herpes simplex virus-1 encoding full-length antibodies could improve immune-virotherapy for glioblastoma.

摘要

溶瘤单纯疱疹病毒 1 能够裂解肿瘤细胞,同时提醒免疫系统。CD47 与 SIRPα 合作,代表了一种重要的免疫检查点,以抑制先天免疫细胞的吞噬作用。在这里,我们展示了表达全长抗(α)-人 CD47 IgG1 或 IgG4 抗体的溶瘤单纯疱疹病毒对胶质母细胞瘤的局部控制。病毒感染的胶质母细胞瘤细胞分泌的抗体阻断了 CD47 的“不要吃我”信号,无论抗体的亚类如何;然而,由于巨噬细胞的抗体依赖细胞吞噬作用和 NK 细胞的抗体依赖细胞细胞毒性,αCD47-IgG1 比αCD47-IgG4 具有更强的肿瘤杀伤作用。颅内注射产生αCD47-IgG1 的病毒会在肿瘤微环境中持续释放相应的抗体,但不会进入体循环;此外,与联合使用局部αCD47-IgG1 的对照溶瘤单纯疱疹病毒相比,产生αCD47-IgG1 的病毒也能更好地提高荷瘤小鼠的存活率。免疫功能正常的小鼠肿瘤模型的结果进一步证实,巨噬细胞,以及在较小程度上的 NK 细胞,介导产生抗体的溶瘤单纯疱疹病毒的抗肿瘤细胞毒性。总之,编码全长抗体的溶瘤单纯疱疹病毒 1 可以改善胶质母细胞瘤的免疫病毒疗法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e492/8501058/f1c3ad1497f0/41467_2021_26003_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e492/8501058/7ac979d28fa0/41467_2021_26003_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e492/8501058/44f41648722d/41467_2021_26003_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e492/8501058/d2d3d8e2b392/41467_2021_26003_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e492/8501058/34342d2b476e/41467_2021_26003_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e492/8501058/7f78082b1036/41467_2021_26003_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e492/8501058/6cc052752f3f/41467_2021_26003_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e492/8501058/f1c3ad1497f0/41467_2021_26003_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e492/8501058/7ac979d28fa0/41467_2021_26003_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e492/8501058/44f41648722d/41467_2021_26003_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e492/8501058/d2d3d8e2b392/41467_2021_26003_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e492/8501058/34342d2b476e/41467_2021_26003_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e492/8501058/7f78082b1036/41467_2021_26003_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e492/8501058/6cc052752f3f/41467_2021_26003_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e492/8501058/f1c3ad1497f0/41467_2021_26003_Fig7_HTML.jpg

相似文献

1
An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma.表达全长抗体的溶瘤病毒增强胶质母细胞瘤的抗肿瘤先天免疫反应。
Nat Commun. 2021 Oct 8;12(1):5908. doi: 10.1038/s41467-021-26003-6.
2
Targeting Fc Receptor-Mediated Effects and the "Don't Eat Me" Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer.用表达抗 CD47 抗体的溶瘤病毒靶向 Fc 受体介导的作用和“别吃我”信号治疗转移性卵巢癌。
Clin Cancer Res. 2022 Jan 1;28(1):201-214. doi: 10.1158/1078-0432.CCR-21-1248. Epub 2021 Oct 13.
3
Mitochondrial metabolic reprogramming of macrophages and T cells enhances CD47 antibody-engineered oncolytic virus antitumor immunity.巨噬细胞和T细胞的线粒体代谢重编程增强了CD47抗体工程化溶瘤病毒的抗肿瘤免疫力。
J Immunother Cancer. 2024 Dec 4;12(12):e009768. doi: 10.1136/jitc-2024-009768.
4
Enhanced treatment of breast cancer brain metastases with oncolytic virus expressing anti-CD47 antibody and temozolomide.用表达抗CD47抗体的溶瘤病毒和替莫唑胺强化治疗乳腺癌脑转移
Mol Ther Oncol. 2024 Jun 5;32(3):200824. doi: 10.1016/j.omton.2024.200824. eCollection 2024 Sep 19.
5
The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.巨噬细胞和小胶质细胞分泌的肿瘤坏死因子α对胶质母细胞瘤肿瘤微环境中溶瘤性单纯疱疹病毒1型治疗的影响
Clin Cancer Res. 2015 Jul 15;21(14):3274-85. doi: 10.1158/1078-0432.CCR-14-3118. Epub 2015 Mar 31.
6
An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma.表达 IL15/IL15Rα 的溶瘤病毒联合即用型 EGFR-CAR NK 细胞靶向胶质母细胞瘤。
Cancer Res. 2021 Jul 1;81(13):3635-3648. doi: 10.1158/0008-5472.CAN-21-0035. Epub 2021 May 18.
7
Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity.携带抗CD47纳米抗体的溶瘤痘苗病毒通过增强固有免疫和适应性免疫对多种肿瘤模型产生强大的抗肿瘤作用。
J Immunother Cancer. 2024 Dec 22;12(12):e009473. doi: 10.1136/jitc-2024-009473.
8
Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.细胞外基质修饰增强胶质母细胞瘤溶瘤腺病毒免疫治疗。
Clin Cancer Res. 2021 Feb 1;27(3):889-902. doi: 10.1158/1078-0432.CCR-20-2400. Epub 2020 Nov 30.
9
A SIRPα-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer.一种 SIRPα-Fc 融合蛋白增强了溶瘤腺病毒对卵巢癌的抗肿瘤作用。
Mol Oncol. 2020 Mar;14(3):657-668. doi: 10.1002/1878-0261.12628. Epub 2020 Feb 7.
10
A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.表皮生长因子受体嵌合抗原受体自然杀伤细胞与溶瘤性单纯疱疹病毒1联合治疗乳腺癌脑转移
Oncotarget. 2016 May 10;7(19):27764-77. doi: 10.18632/oncotarget.8526.

引用本文的文献

1
Targeting Macrophages in Glioblastoma: Current Therapies and Future Directions.胶质母细胞瘤中巨噬细胞的靶向治疗:当前疗法与未来方向
Cancers (Basel). 2025 Aug 18;17(16):2687. doi: 10.3390/cancers17162687.
2
New Insights into Monocyte-Derived Macrophages in Glioblastoma.胶质母细胞瘤中单核细胞衍生巨噬细胞的新见解
Research (Wash D C). 2025 Aug 12;8:0836. doi: 10.34133/research.0836. eCollection 2025.
3
Research and Clinical Progress of Therapeutic Tumor Vaccines.治疗性肿瘤疫苗的研究与临床进展

本文引用的文献

1
An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma.表达 IL15/IL15Rα 的溶瘤病毒联合即用型 EGFR-CAR NK 细胞靶向胶质母细胞瘤。
Cancer Res. 2021 Jul 1;81(13):3635-3648. doi: 10.1158/0008-5472.CAN-21-0035. Epub 2021 May 18.
2
Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.卡巴他赛对巨噬细胞的作用改善了针对 CD47 的免疫疗法在三阴性乳腺癌中的疗效。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-002022.
3
Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
Vaccines (Basel). 2025 Jun 23;13(7):672. doi: 10.3390/vaccines13070672.
4
Oncolytic adenovirus serotype 35 mediated tumor growth suppression efficient activation of antitumor immunity.35型溶瘤腺病毒介导肿瘤生长抑制及抗肿瘤免疫的有效激活。
J Immunother Cancer. 2025 Jul 10;13(7):e006558. doi: 10.1136/jitc-2022-006558.
5
Commentary on "Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors".关于“溶瘤腺病毒靶向释放双特异性融合蛋白SIRPα/Siglec-10可恢复肿瘤相关巨噬细胞活力以改善实体瘤治疗效果”的评论
J Immunother Cancer. 2025 Jun 15;13(6):e012218. doi: 10.1136/jitc-2025-012218.
6
The Era of Precision Medicine: Advancing Treatment Paradigms for Small Cell Lung Cancer.精准医学时代:推进小细胞肺癌的治疗模式
Cancers (Basel). 2025 May 31;17(11):1847. doi: 10.3390/cancers17111847.
7
Novel immunotherapy for gastric cancer: targeting the CD47-SIRPα axis.胃癌的新型免疫疗法:靶向CD47-SIRPα轴。
Cancer Metastasis Rev. 2025 May 29;44(2):52. doi: 10.1007/s10555-025-10269-z.
8
Oncolytic viruses targeting CD47: a new road to success?靶向CD47的溶瘤病毒:通往成功的新途径?
J Immunother Cancer. 2025 May 7;13(5):e011550. doi: 10.1136/jitc-2025-011550.
9
An oncolytic vaccinia virus expressing anti-CD47 nanobody exerts enhanced antitumor activity by mediating innate and adaptive immune cell infiltration and activation in the lymphoma tumor microenvironment.一种表达抗CD47纳米抗体的溶瘤痘苗病毒通过介导淋巴瘤肿瘤微环境中固有免疫细胞和适应性免疫细胞的浸润与激活,发挥增强的抗肿瘤活性。
Haematologica. 2025 Apr 10. doi: 10.3324/haematol.2024.286923.
10
Generalization of neoantigen-based tumor vaccine by delivering peptide-MHC complex via oncolytic virus.通过溶瘤病毒递送肽-主要组织相容性复合体实现基于新抗原的肿瘤疫苗的广泛应用。
EMBO Mol Med. 2025 May;17(5):1118-1152. doi: 10.1038/s44321-025-00225-3. Epub 2025 Apr 7.
胶质母细胞瘤中的不同 T 细胞亚群及靶向免疫治疗。
Cancer Lett. 2021 Jan 1;496:134-143. doi: 10.1016/j.canlet.2020.09.028. Epub 2020 Oct 3.
4
Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways.免疫检查点抑制在髓系恶性肿瘤中的应用:超越 PD-1/PD-L1 和 CTLA-4 通路。
Blood Rev. 2021 Jan;45:100709. doi: 10.1016/j.blre.2020.100709. Epub 2020 May 23.
5
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.在晚期癌症患者中进行的抗 CD47 抗体 Hu5F9-G4 的首例人体、首例同类药物的 I 期临床试验。
J Clin Oncol. 2019 Apr 20;37(12):946-953. doi: 10.1200/JCO.18.02018. Epub 2019 Feb 27.
6
Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma.小胶质细胞是 CD47-SIRPα 抗吞噬轴破坏对抗神经胶质瘤的效应细胞。
Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):997-1006. doi: 10.1073/pnas.1721434116. Epub 2019 Jan 2.
7
An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma.一种表达E-钙黏蛋白的溶瘤性疱疹病毒可提高胶质母细胞瘤小鼠模型的生存率。
Nat Biotechnol. 2018 Nov 26. doi: 10.1038/nbt.4302.
8
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.Hu5F9-G4 联合利妥昔单抗阻断 CD47 在非霍奇金淋巴瘤中的作用。
N Engl J Med. 2018 Nov 1;379(18):1711-1721. doi: 10.1056/NEJMoa1807315.
9
Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy.用针对 PD-1 的单链抗体片段修饰单纯疱疹病毒 1 用于实验性脑胶质瘤治疗。
Clin Cancer Res. 2019 Jan 1;25(1):290-299. doi: 10.1158/1078-0432.CCR-18-2311. Epub 2018 Oct 2.
10
A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety.一种新型全人源抗 CD47 抗体,作为一种具有良好安全性的人类肿瘤潜在疗法。
Biochimie. 2018 Aug;151:54-66. doi: 10.1016/j.biochi.2018.05.019. Epub 2018 Jun 1.